Author: Bhalla, Anurag; Mukherjee, Manali; Radford, Katherine; Nazy, Ishac; Kjarsgaard, Melanie; Bowdish, Dawn M.E.; Nair, Parameswaran
Title: Dupilumab, Severe Asthma Airway Responses, and SARSâ€CoV2 Serology Cord-id: okq0h4ng Document date: 2020_8_6
ID: okq0h4ng
Snippet: There is paucity of evidence assessing immune responses to COVIDâ€19 in severe asthmatics treated with biologics. Recent guidelines recommend continuing these agents (as clinically indicated) to maintaining asthma control. Supporting this claim, Lommatzsch demonstrated that omalizumab could safely be continued during active COVIDâ€19 infection in a patient with allergic asthma.(1) There are other emerging reports that show that treatment with benralizumab(2) and dupilumab(3) is not associated
Document: There is paucity of evidence assessing immune responses to COVIDâ€19 in severe asthmatics treated with biologics. Recent guidelines recommend continuing these agents (as clinically indicated) to maintaining asthma control. Supporting this claim, Lommatzsch demonstrated that omalizumab could safely be continued during active COVIDâ€19 infection in a patient with allergic asthma.(1) There are other emerging reports that show that treatment with benralizumab(2) and dupilumab(3) is not associated with significant negative impact. We had similar experience in a young patient with severe asthma treated with dupilumab.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date